ASTCT

The American Society for Transplantation and Cellular Therapy Scientific Journal: @ASTCT_Journal #Tandem27

[ASTCT @ASTCT]

Influence. Innovate. Growth. ASTCT President Margaret MacMillan, MD, MSc, FRCPC and Past President David Porter, MD, discuss the future of ASTCT and the priorities shaping our 2026–2028 Strategic Plan. Watch to learn more: https://t.co/G7nRJAYCce

[ASTCT @ASTCT]

Discover how an ASTCT membership can power your practice. For a limited time, join ASTCT to receive member benefits through 2027. Learn more: https://t.co/INkHQDtFBL

[ASTCT @ASTCT]

The June issue of @ASTCTJournal, 'Transplantation and Cellular Therapy,' is now available online: https://t.co/NP02O2UUcL

[ASTCT @ASTCT]

In the ‘ASTCT Talks’ episode "Gene Therapy Today and Tomorrow," Dr. Nirali Shah is joined by Dr. Christy Duncan and Dr. Sung-Yun Pai to talk through recent developments in gene therapy research, accessibility and deliverability. Listen on Nucleus or your favorite app: https://t.co/agBvoSo8ow

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This study shows that PTCy-based #GVHD prophylaxis enables successful #alloHCT for patients with SAA lacking an MSD. Using bone marrow grafts from MUD and MMUD, they observed universal engraftment, absent TRM and excellent long-term survival. https://t.co/ScTcpzsjaM

[ASTCT @ASTCT]

Save the date📅 Registration for CEC opens in July! Designed for APPs, nurses & fellows, this conference provides practical insights you can implement in practice. Learn more: https://t.co/HaPWHNsdrx

[ASTCT @ASTCT]

This World Blood Donor Day, we'd like to recognize and thank the blood donors whose generosity helps save and improve lives every day.

For patients undergoing hematopoietic cell transplantation and cellular therapy, donated blood is often a critical part of treatment and recover. Thank you to all who give❤️🩸
#GiveBlood #WorldBloodDonorDay

[ASTCT @ASTCT]

In this ASTCT Board Member Spotlight, Sophie Paczesny, MD, PhD, reflects on her work advancing GVHD biomarker research and immunotherapy innovation, shares her priorities as an ASTCT board member and offers insights on the current opportunities and challenges in the field.

Read the full spotlight: https://t.co/6p38QbO2bJ

[ASTCT @ASTCT]

At this upcoming ASTCT Cord Blood SIG webinar on July 1, researchers will discuss the role of cord blood as a graft source for patients with difficult-to-cure acute leukemia, exploring clinical outcomes and real-world applications through roundtable discussion.

Register now and join colleagues for a conversation on the latest developments in cord blood transplantation: https://t.co/9gizwKgBm5

[ASTCT @ASTCT]

The #Tandem27 Pharmacy Track is seeking speakers for the 2027 meetings in Orlando! Topics for 2027 include grants, solid tumors, gene therapy, GVHD and more. Visit the link below to learn more and apply by Friday, July 3.
Apply now: https://t.co/Nw933JTdwG

[ASTCT @ASTCT]

ASTCT's comment letter responding to the @CMSGov FY 2027 IPPS Proposed Rule is now available to view. Read the letter to review the Society’s recommendations for CMS: https://t.co/LC3sRhX8eS

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

The June issue of 'Transplantation and Cellular Therapy,' is now available online: https://t.co/RhWwkIqKeR
@ELShematology

[ASTCT @ASTCT]

This special GVHD supplement explores the diagnosis and treatment of cutaneous cGVHD, warning signs of ocular GVHD and the importance of addressing the physical and psychosocial needs of patients with GVHD.

Read in English: https://t.co/ZcMwfCjpqZ
Read in Spanish: https://t.co/bZVyKk0P5f

[ASTCT @ASTCT]

For 30 years, 'Transplantation and Cellular Therapy' has advanced the science and practice of HCT and cellular therapies. @ASTCT_Journal

ASTCT President Margy MacMillan reflects on the journal's impact and continued importance to the field.

https://t.co/wBTNIdqddi

[ASTCT @ASTCT]

Explore two hot topics with the ASTCT Pharmacy SIG! Join the journal club to discuss:

✅Brexucabtagene autoleucel in BTKi naive relapsed/refractory mantle cell lymphoma
✅Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide maintenance post transplant in multiple myeloma

Register today: https://t.co/v3NPNke4xV

[ASTCT @ASTCT]

In our latest episode of ASTCT Talks, Dr. Nirali Shah is joined by Dr. Christy Duncan and Dr. Sung‑Yun Pai to talk through recent progress in the field and what it actually takes to deliver these treatments at the patient level. The discussion draws on their experience in transplant and genetic disease, covering both scientific advances and the operational challenges that come with implementing gene therapy—especially in complex and resource‑intensive settings. Listen now on Nucleus or wherever you get your podcasts. https://t.co/C5aeuySsgK

[ASTCT @ASTCT]

Dr. Zahra Mahmoudjafari, PharmD, BCOP, FHOPA, MBA, is the first author of the article “From Vision to Viability: Developing Infrastructure for Cell and Gene Therapy Programs.” She shares in this Q&A background on how this research came about, findings that particularly surprised her, and how these findings are guiding current and future initiatives.
https://t.co/hOVFUsLqFD

[ASTCT @ASTCT]

The May issue of ASTCT's journal, 'Transplantation and Cellular Therapy,' is now available online: https://t.co/NP02O2UUcL @ELShematology @ASTCT_Journal

[ASTCT @ASTCT]

How is the role of upfront BMT changing for patients with severe aplastic anemia?

Join us tomorrow for a webinar reviewing current evidence, patient selection, donor sources, conditioning strategies and practical case-based considerations. Register: https://t.co/a6B5C5Md3h

[ASTCT @ASTCT]

Stay current on emerging evidence in transplantation and cellular therapy.

At the next ASTCT Pharmacy Journal Club, presenters will review data from the ATLAS trial evaluating KRd maintenance after ASCT in multiple myeloma and the ZUMA-2 Cohort 3 analysis of brexucabtagene autoleucel in BTKi-naive relapsed/refractory mantle cell lymphoma.

Register: https://t.co/cCSBxgFz7o

[Transplantation and Cellular Therapy Journal @ASTCT_Journal]

This review article highlights how regulatory T cells can suppress acute and chronic #GVHD while preserving graft-versus-leukemia effects after #alloHCT. Early clinical studies demonstrate promising GVHD control low relapse rates and favorable survival. https://t.co/jd3taskfW5